Nuveen Asset Management LLC Sells 9,998 Shares of Moderna, Inc. (NASDAQ:MRNA)

Nuveen Asset Management LLC trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 1.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 672,179 shares of the company's stock after selling 9,998 shares during the period. Nuveen Asset Management LLC owned approximately 0.17% of Moderna worth $27,949,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Norges Bank acquired a new stake in shares of Moderna during the 4th quarter worth approximately $163,833,000. FMR LLC grew its position in shares of Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after buying an additional 1,282,469 shares during the period. Pictet Asset Management Holding SA grew its position in shares of Moderna by 170.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock worth $73,447,000 after buying an additional 1,113,455 shares during the period. Invesco Ltd. lifted its holdings in shares of Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after purchasing an additional 979,858 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Moderna by 225.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company's stock worth $42,027,000 after purchasing an additional 700,458 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

MRNA stock traded up $0.51 during mid-day trading on Tuesday, reaching $26.77. 10,499,664 shares of the company traded hands, compared to its average volume of 8,019,753. The company has a market capitalization of $10.35 billion, a P/E ratio of -2.89 and a beta of 1.99. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $164.73. The company has a fifty day moving average price of $26.94 and a 200-day moving average price of $34.25.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company's revenue for the quarter was down 35.3% on a year-over-year basis. During the same quarter last year, the company posted ($3.07) EPS. As a group, analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on MRNA shares. Morgan Stanley cut their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. UBS Group dropped their price objective on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. William Blair restated a "market perform" rating on shares of Moderna in a research note on Thursday, April 17th. Bank of America decreased their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Finally, The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and decreased their target price for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Moderna presently has a consensus rating of "Hold" and an average price target of $53.58.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.